Chemotherapy resistance abrogation in metastatic melanoma

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 4, 2010, Pages 259-266

  Tawbi, Hussein A ^a   Buch, Shama C ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Drug development; Drug resistance; Melanoma; Mismatch repair; O6 methylguanine methyltransferase; PARP inhibitor

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 4 IODO 3 NITROBENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; 6 O BENZYLGUANINE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ALKYLATING AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DNA; GEMCITABINE; INO 1001; IRINOTECAN; LOMEGUATRIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OBLIMERSEN; OLAPARIB; PACLITAXEL; PLATINUM COMPLEX; PROTEIN BCL 2; PROTEIN INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; COLON CANCER; CYTOTOXICITY; DNA REPAIR; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EXCISION REPAIR; GLIOMA; HUMAN; LYMPHOMA; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MISMATCH REPAIR; NONHUMAN; REVIEW; SARCOMA; SOLID TUMOR; TUMOR XENOGRAFT; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METASTASIS; PHYSIOLOGY;

APOPTOSIS; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 77954058743     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009. Available at http://www.cancer.org/downloads/STT/500809web.pdf.
2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
3. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 2005;6:185-193.
4. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007;34:532-545.
5. Middleton MR, Grobb JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
6. Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am. 2009;23:583-597.
7. Laber DA, Okeke RI, Arce-Lara C, et al. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol. 2006;132:611-616.
8. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasis. Cancer. 1990;66:1873-1878.
9. Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987;71:171-172.
10. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574-578.
11. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol. 1984;2:316-319.
12. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2895-2899.
13. Flaherty KT Brose M, Schluchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrate preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22(14 suppl):Abstract 7507.
14. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):Abstract 8510.
15. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12:328-331.
16. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296-307.
17. Pegg AE. Repair of O6-alkylguanine by alkyltransferases. Mutat Res. 2000; 462:83-100.
18. Spiro TP, Gerson SL, Liu L, et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 1999;59:2402-2410.
19. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000;6:3025-3031.
20. Schold SC Jr, Kokkinakis DM, Chang SM, et al. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neurooncology. 2004;6:28-32.
21. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin Oncol. 2000;18:3522-3528.
22. Weingart J, Grossman SA, Carson KA, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007;25:399-404.
23. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178-7187.
24. Warren KE, Aikin AA, Libucha M. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol. 2005;23:7646-7653.
25. Gajewski TF, Sosman J, Gerson SL, et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1- nitrosourea in advanced melanoma. Clin Cancer Res. 2005;11:7861-7865.
26. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O(6)- benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002;20:2277-2283.
27. Ryan CW, Dolan ME, Brockstein BB, et al. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006;58:634-639.
28. Batts ED, Maisel C, Kane D, et al. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother Pharmacol. 2007;60:415-421.
29. Tawbi HA, Tarhini A, Moschos S, et al. Phase I trial of lomeguatrib (Patrin, PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24(18S):Abstract 8016.
30. Ranson M, Hersey P, Thompson D, et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol. 2007;25:2540-2545.
31. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine- DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
32. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage iv malignant melanoma: final results of the randomized phase III study (EORTC 18032). Ann Oncol. 2008;19(suppl 8):LBA8.
33. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
34. Sabharwal A, Waters R, Danson S, et al. Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res. 2009 Jun 25 [Epub ahead of print].
35. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA. 2003;100:776-781.
36. Sobol RW, Tawbi H, Jukic DM, et al. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:Abstract 8015.
37. US Food and Drug Administration Web site. FDA approves new treatment for myelodysplastic syndromes (MDS). Available at www.fda.gov. [cited 2006 July 4].
38. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039-6044.
39. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603-4609.
40. Quinn AG, Healy E, Rehman I, et al. Microsatellite instability in human nonmelanoma and melanoma skin cancer. J Invest Dermatol. 1995;104:309-312.
41. Korabiowska M, Brinck U, Dengler H, et al. Analysis of the DNA mismatch repair proteins expression in malignant melanomas. Anticancer Res. 2000;20: 4499-4505.
42. Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs. 2004;15:421-426.
43. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
44. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
45. Woon EC, Threadgill MD. Poly(ADP-ribose)polymerase inhibition-where now? Curr Med Chem. 2005;12:2373-2392.
46. Horvath EM, Szabo C. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Drug News Perspect. 2007;20:171-181.
47. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
48. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs. 2009;18:31-43.
49. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull. 2009;89:23-40.
50. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728-37.
51. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
52. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24(18S):Abstract 8013.
53. Kummar S, Kinders R, Gutierrez M, et al. Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a phase 0 trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):Abstract 3518.
54. Yang SX, Kummar S, Rubinstein L, et al. Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: immunohistochemistry results. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 3580.
55. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 3577.
56. Mahany JJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 3579.
57. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27(18S):Abstract 3.
58. US Food and Drug Administration Web site. Available at: http://www.fda.org.
59. Wang C, Bedikian A, Kim K, et al. Evaluation of tolerability, safety and pharmacokinetics of INO-1001 plus temozolomide (TMZ) in patients with unresectable stage III/IV melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24(18S):Abstract 12015.
60. Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 2005;11:3402-3409.
61. Kinders RJ, PalmaJ, Liu X, et al. Development of a quantitative enzyme inmmunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity. Presented at: 2006 AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development; September 12-15, 2006; Chicago, IL.
62. Fong PC, Spicer J, Reade S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. Proc Am Soc Clin Oncol. 2006;25:A3022
63. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99:451-454.
64. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000;356:1728-1733.
65. Mooy CM, Luyten GP, de Jong PT, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol. 1995;147:1097-1104.
66. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother. 2003;4:2205-2211.
67. Zhao R, Goldman ID. Resistance to antifolates. Oncogene. 2003;22: 7431-7457.
68. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells invitro and invivo. Clin Cancer Res. 2003;9:2826-2836.
69. Gonzalez R, Lewis K, Samlowski W et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or IV melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25:Abstract 8538.